ATE547425T1 - Optimiertes dengue-virus-eintrittshemmendes peptid (dn81) - Google Patents

Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)

Info

Publication number
ATE547425T1
ATE547425T1 AT08836872T AT08836872T ATE547425T1 AT E547425 T1 ATE547425 T1 AT E547425T1 AT 08836872 T AT08836872 T AT 08836872T AT 08836872 T AT08836872 T AT 08836872T AT E547425 T1 ATE547425 T1 AT E547425T1
Authority
AT
Austria
Prior art keywords
dengue virus
virus entry
inhibiting peptide
optimized
optimized dengue
Prior art date
Application number
AT08836872T
Other languages
English (en)
Inventor
Scott F Michael
Sharon Isern
Robert Garry
Ram Samudrala
Joshua Costin
Ekachai Jenwitheesuk
Original Assignee
Florida Gulf Coast University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florida Gulf Coast University filed Critical Florida Gulf Coast University
Application granted granted Critical
Publication of ATE547425T1 publication Critical patent/ATE547425T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08836872T 2007-07-13 2008-07-11 Optimiertes dengue-virus-eintrittshemmendes peptid (dn81) ATE547425T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94971007P 2007-07-13 2007-07-13
PCT/US2008/069716 WO2009048658A2 (en) 2007-07-13 2008-07-11 Optimized dengue virus entry inhibitory peptide (dn81)

Publications (1)

Publication Number Publication Date
ATE547425T1 true ATE547425T1 (de) 2012-03-15

Family

ID=40549787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08836872T ATE547425T1 (de) 2007-07-13 2008-07-11 Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)

Country Status (10)

Country Link
US (1) US8541377B2 (de)
EP (1) EP2178903B1 (de)
CN (1) CN101801996B (de)
AP (1) AP3172A (de)
AT (1) ATE547425T1 (de)
AU (1) AU2008311220B2 (de)
CO (1) CO6260142A2 (de)
DK (1) DK2178903T3 (de)
EC (1) ECSP109947A (de)
WO (1) WO2009048658A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3166063A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
US10639380B2 (en) * 2016-12-06 2020-05-05 Ennaid Therapeutics, LLC Flavivirus-binding, entry-obstructing, protease-resistant peptide (RI57)
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
IL298307A (en) 2018-09-05 2023-01-01 Takeda Vaccines Inc Dengue fever vaccine unit dose and its administration
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same

Also Published As

Publication number Publication date
US20110112031A1 (en) 2011-05-12
ECSP109947A (es) 2010-05-31
US8541377B2 (en) 2013-09-24
WO2009048658A9 (en) 2009-06-11
AP2010005141A0 (en) 2010-02-28
EP2178903A4 (de) 2010-11-17
WO2009048658A3 (en) 2009-07-23
HK1145693A1 (en) 2011-04-29
EP2178903A2 (de) 2010-04-28
AP3172A (en) 2015-03-31
WO2009048658A2 (en) 2009-04-16
AU2008311220B2 (en) 2013-10-03
EP2178903B1 (de) 2012-02-29
DK2178903T3 (da) 2012-06-18
CN101801996B (zh) 2013-06-12
CN101801996A (zh) 2010-08-11
AU2008311220A1 (en) 2009-04-16
CO6260142A2 (es) 2011-03-22

Similar Documents

Publication Publication Date Title
EP2118122A4 (de) Neuartige antimikrobielle peptide
ATE451392T1 (de) Gegen amyloid-beta peptid gerichtete antikörper
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
EP2093287A4 (de) Igg bindendes peptid
EP1961761A4 (de) Neue peptidverbindung
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
BRPI0914889A2 (pt) peptídeo glp-1 adicionado de cadeia oligossacarídica
BRPI0911743A2 (pt) "peptídeo"
DK2035447T3 (da) Polypeptid
BRPI0814587A2 (pt) Peptídeos antibióticos
DK2035451T3 (da) Insulinoptrop peptidsyntese
DE602005015131D1 (de) Interleukin-15-antagonistisches peptid
DK3115370T3 (da) Biologisk aktive peptider
EP2027271A4 (de) Rekombinante vektoren
DK2001518T3 (da) Cykliske natriuretiske peptidfremstillinger
EP2010561A4 (de) Antimikrobielle peptide
EP2061805A4 (de) Rekombinantes hcv-e2-glykoprotein
ATE547425T1 (de) Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)
EP1858914A4 (de) Peptidnetze
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider
EP2101804A4 (de) Proangiogene peptide
EP2285827A4 (de) Peptide und ihre verwendung
ATE541856T1 (de) Stark verbrückte peptide aus der actinomadura namibiensis
EP2280988A4 (de) Angiogenes peptid
DK2021364T3 (da) Forbedrede antimikrobielle peptider